Granted Patent B2

US 10,539,575 · App. 14/889,930 · Granted Jan 21, 2020

Inventors: Regis Perichon (Cary, NC); Jeffery Edmond Cobb (Chapel Hill, NC); Meredith V. Brown (Durham, NC); Adam Kennedy (Durham, NC)

Assignee: METABOLON, INC.

G01N33/6893G01N33/5308G01N33/64G01N33/6848G01N33/70G01N2570/00G01N2800/347G01N2800/50G01N2800/52G01N2800/56

Abstract

Claims (45)

1. A method of determining and treating kidney function impairment in a subject, the method comprising:

a) extracting small molecules from a biological sample obtained from the subject to produce an analytical sample;

b) performing or having performed an assay on the analytical sample to determine the level(s) of one or more biomarkers, wherein the one or more biomarkers are selected from the group consisting of the following biomarkers: N-acetylthreonine, N-acetylalanine, arabitol, N-acetylserine, erythronate, 4-acetamidobutanoate, N6-carbamoylthreonyladenosine, N-acetylcarnosine, arabonate, xylonate, N-formylmethionine, O-methylcatechol sulfate, N-acetylmethionine, N2,N5-diacetylornithine, ribose, pyroglutamine, 5-methylthioadenosine (MTA), 1-methylurate, pro-hydroxy-pro, N-acetyl-3-methylhistidine, 2,3-dihydroxyisovalerate, trigonelline (N′-methylnicotinate), X-11564, and X-17299;

c) determining kidney function impairment in the subject by comparing the level(s) of the one or more biomarkers in the sample to kidney function reference levels of the one or more biomarkers in order to determine impaired kidney function in the subject; and

d) administering an effective treatment to the subject having impaired kidney function, wherein effective treatment comprises one or more of weight loss, healthy diet, smoking cessation, high blood pressure treatment, performing or having performed dialysis, or performing or having performed a kidney transplant.

2. The method of claim 1 , further comprising

performing or having performed an assay on the analytical sample to determine the level(s) of one or more additional biomarkers selected from the group consisting of the following biomarkers: trans-4-hydroxyproline, myo-inositol, kynurenine, tryptophan, 3-methylhistidine, erythritol, urea, 3-methylglutarylcarnitine (C6), S-adenosylhomocysteine (SAH), N1-methyladenosine, N2,N2-dimethylguanosine, p-cresol sulfate, succinylcarnitine, 2-methylbutyrylcarnitine (C5), N4-acetylcytidine, N1-Methyl-2-pyridone-5-carboxamide, 1-methylhistidine, tiglyl carnitine, isobutyrylcarnitine, indolelactate, glutarylcarnitine (C5), choline, hydroxyisovaleroyl carnitine, scyllo-inositol, quinate, salicyluric glucuronide, 2-mannopyranosyl tryptophan (2-MPT), creatinine, phenylacetyl-L-glutamine, 3-indoxylsulfate, pseudouridine, N6-acetyllysine, threitol and 2-hydroxyhippurate (salicylurate).

3. The method of claim 1 , further comprising using the determined levels of the one or more biomarkers in a mathematical model to calculate an estimated glomerular filtration rate (GFR) to determine kidney function impairment.

4. The method of claim 3 , wherein the sample is analyzed using one or more techniques selected from the group consisting of mass spectrometry, ELISA, and antibody linkage.

5. The method of claim 1 , wherein the sample is obtained from a subject that has no symptoms of impaired kidney function.

6. The method of claim 1 , wherein the subject has been previously diagnosed with hypertension and/or diabetes.

7. The method of claim 1 , wherein the subject has symptoms of impaired kidney function.

8. The method of claim 1 , wherein the subject is one for whom kidney function assessment using conventional methods is difficult.

9. The method of claim 8 , wherein the subject is selected from the group consisting of the following: obese, very lean, vegetarian, chronically ill, and elderly.

10. The method of claim 1 , further comprising performing additional analysis related to the one or more additional markers and methods and/or measures comprising BUN, serum creatinine (SCr), urine albumin measurements, family history of chronic kidney disease (CKD), β-2 microglobulin, or β-TRACE, and combining results of the additional analysis with the assessment results from the initial assessment steps.

11. A method of preventing impaired kidney function in a subject being considered for treatment with a composition wherein the composition is selected from the group consisting of a chemotherapeutic agent, an antibiotic, and a contrast imaging agent, wherein the composition may have a toxic effect on the kidneys, the method comprising:

a) extracting small molecules from a biological sample obtained from the subject to produce an analytical sample;

b) performing, or having performed, an assay on the analytical sample to determine the level(s) of one or more biomarkers, wherein the one or more biomarkers are selected from the group consisting of the following biomarkers: N-acetylthreonine, N-acetylalanine, arabitol, N-acetylserine, erythronate, 4-acetamidobutanoate, N6-carbamoylthreonyladenosine, N-acetylcarnosine, arabonate, xylonate, N-formylmethionine, O-methylcatechol sulfate, N-acetylmethionine, N2,N5-diacetylornithine, ribose, pyroglutamine, 5-methylthioadenosine (MTA), 1-methylurate, pro-hydroxy-pro, N-acetyl-3-methylhistidine, 2,3-dihydroxyisovalerate, trigonelline (N′-methylnicotinate), X-11564, and X-17299; and

c) performing or having performed an assay on the analytical sample to determine the level(s) of one or more additional biomarkers selected from the group consisting of the following biomarkers: trans-4-hydroxyproline, myo-inositol, kynurenine, tryptophan, 3-methylhistidine, erythritol, urea, 3-methylglutarylcarnitine (C6), S-adenosylhomocysteine (SAH), N1-methyladenosine, N2,N2-dimethylguanosine, p-cresol sulfate, succinylcarnitine, 2-methylbutyrylcarnitine (C5), N4-acetylcytidine, N1-Methyl-2-pyridone-5-carboxamide, 1-methylhistidine, tiglyl carnitine, isobutyrylcarnitine, indolelactate, glutarylcarnitine (C5), choline, hydroxyisovaleroyl carnitine, scyllo-inositol, quinate, salicyluric glucuronide, 2-mannopyranosyl tryptophan (2-MPT), creatinine, phenylacetyl-L-glutamine, 3-indoxylsulfate, pseudouridine, N6-acetyllysine, threitol and 2-hydroxyhippurate (salicylurate); and

d) using the determined levels of the one or more biomarkers and, optionally, the one or more additional biomarkers, in a mathematical model to calculate an estimated glomerular filtration rate (GFR);

e) using the estimated GFR to determine kidney function in the subject, and

i. administering the chemotherapeutic agent, antibiotic, and/or contrast imaging agent to the subject having normal kidney function,

ii. decreasing the dosage of the chemotherapeutic agent, antibiotic, and/or contrast imaging agent or selecting a different chemotherapeutic agent, antibiotic, and/or contrast imaging agent to administer to the subject having moderately impaired kidney function, or

iii. decreasing the dosage of the chemotherapeutic agent, antibiotic, and/or contrast imaging agent, selecting a different chemotherapeutic agent, antibiotic, and/or contrast imaging agent, or selecting a different treatment intervention or diagnostic test for the subject having severely impaired kidney function.

12. A method of monitoring kidney function to prevent impaired kidney function in a subject wherein the subject has been treated with a composition that may impair kidney function, wherein the composition is administered to a subject to treat a disease or condition and wherein risk of kidney damage from treatment with the composition for a subject having impaired kidney function is higher than for a subject not having impaired kidney function, the method comprising:

a) extracting small molecules from a biological sample obtained from a subject treated with a composition that may have a toxic effect on the kidneys;

b) performing or having performed an assay on a first biological sample from the subject to determine the level(s) of one or more biomarkers for kidney function, where the one or more biomarkers are selected from the group consisting of the following biomarkers: N-acetylthreonine, N-acetylalanine, arabitol, N-acetylserine, erythronate, 4-acetamidobutanoate, N6-carbamoylthreonyladenosine, N-acetylcarnosine, arabonate, xylonate, N-formylmethionine, O-methylcatechol sulfate, N-acetylmethionine, N2,N5-diacetylornithine, ribose, pyroglutamine, 5-methylthioadenosine (MTA), 1-methylurate, pro-hydroxy-pro, N-acetyl-3-methylhistidine, 2,3-dihydroxyisovalerate, trigonelline (N′-methylnicotinate), X-11564, and X-17299;

c) performing or having performed the assay on a second biological sample from the subject to determine the level(s) of the one or more biomarkers for kidney function, wherein the second sample is obtained from the subject at a second time point; and

d) monitoring kidney function in the subject by comparing the level(s) of one or more biomarkers in the second sample to the level(s) of the one or more biomarkers in (a) the first sample and/or (b) kidney function reference levels of the one or more biomarkers, and

i. continuing to administer the composition to the subject having kidney function that remains in a normal range,

ii. decreasing the dosage of the composition or selecting a different composition for treating the subject having kidney function that is moderately impaired, or

iii. discontinuing treatment with the composition and selecting a different composition or treatment regimen; or continuing treatment by administering a decreased dosage of the composition to the subject having kidney function that is severely impaired.

13. The method of claim 12 , further comprising

performing or having performed an assay on the first biological sample and the second biological sample from the subject to determine the level(s) of one or more additional biomarkers selected from the group consisting of the following biomarkers: trans-4-hydroxyproline, myo-inositol, kynurenine, tryptophan, 3-methylhistidine, erythritol, urea, 3-methylglutarylcarnitine (C6), S-adenosylhomocysteine (SAH), N1-methyladenosine, N2,N2-dimethylguanosine, p-cresol sulfate, succinylcarnitine, 2-methylbutyrylcarnitine (C5), N4-acetylcytidine, N1-Methyl-2-pyridone-5-carboxamide, 1-methylhistidine, tiglyl carnitine, isobutyrylcarnitine, indolelactate, glutarylcarnitine (C5), choline, hydroxyisovaleroyl carnitine, scyllo-inositol, quinate, salicyluric glucuronide, 2-mannopyranosyl tryptophan (2-MPT), creatinine, phenylacetyl-L-glutamine, 3-indoxylsulfate, pseudouridine, N6-acetyllysine, threitol and 2-hydroxyhippurate (salicylurate).

14. The method of claim 12 , further comprising using the determined levels of the one or more biomarkers in a mathematical model to calculate an estimated glomerular filtration rate (GFR); and using the estimated GFR to monitor kidney function.

15. A method to determine or aid in the determination of kidney function in a subject who is a potential kidney donor, the method comprising:

a) extracting small molecules from a biological sample obtained from the subject to produce an analytical sample;

b) performing or having performed an assay on the analytical sample from the subject to determine the level(s) of one or more biomarkers, wherein the one or more biomarkers are selected from the group consisting of the following biomarkers: N-acetylthreonine, N-acetylalanine, arabitol, N-acetylserine, erythronate, 4-acetamidobutanoate, N6-carbamoylthreonyladenosine, N-acetylcarnosine, arabonate, xylonate, N-formylmethionine, O-methylcatechol sulfate, N-acetylmethionine, N2,N5-diacetylornithine, ribose, pyroglutamine, 5-methylthioadenosine (MTA), 1-methylurate, pro-hydroxy-pro, N-acetyl-3-methylhistidine, 2,3-dihydroxyisovalerate, trigonelline (N′-methylnicotinate), X-11564, and X-17299;

c) using the determined level(s) of the one or more biomarkers in a mathematical model to calculate an estimated glomerular filtration rate (GFR);

d) using the estimated GFR to determine kidney function of the potential donor, and

e) performing or having performed a kidney transplant using a kidney of the potential donor having normal kidney function.

16. The method of claim 12 , further comprising

performing additional analysis related to one or more additional markers and methods and/or measures comprising BUN, serum creatinine, urine albumin measurements, β-2 microglobulin, β-TRACE, or family history of chronic kidney disease (CKD), wherein the one or more additional biomarkers are selected from the group consisting of trans-4-hydroxyproline, myo-inositol, kynurenine, tryptophan, 3-methylhistidine, erythritol, urea, 3-methylglutarylcarnitine (C6), S-adenosylhomocysteine (SAH), N1-methyladenosine, N2,N2-dimethylguanosine, p-cresol sulfate, succinylcarnitine, 2-methylbutyrylcarnitine (C5), N4-acetylcytidine, N1-Methyl-2-pyridone-5-carboxamide, 1-methylhistidine, tiglyl carnitine, isobutyrylcarnitine, indolelactate, glutarylcarnitine (C5), choline, hydroxyisovaleroyl carnitine, scyllo-inositol, quinate, salicyluric glucuronide, 2-mannopyranosyl tryptophan (2-MPT), creatinine, phenylacetyl-L-glutamine, 3-indoxylsulfate, pseudouridine, N6-acetyllysine, threitol and 2-hydroxyhippurate (salicylurate), and

combining results of the additional analysis with the assessment results from the initial assessment steps.

17. The method of claim 12 , wherein the composition is selected from the group consisting of a chemotherapeutic agent, a contrast imaging agent and an antibiotic.

Assignments (11)

Cited By (1)

US 12,578,322